JP2017534577A5 - - Google Patents

Download PDF

Info

Publication number
JP2017534577A5
JP2017534577A5 JP2017514474A JP2017514474A JP2017534577A5 JP 2017534577 A5 JP2017534577 A5 JP 2017534577A5 JP 2017514474 A JP2017514474 A JP 2017514474A JP 2017514474 A JP2017514474 A JP 2017514474A JP 2017534577 A5 JP2017534577 A5 JP 2017534577A5
Authority
JP
Japan
Prior art keywords
seq
sequence
antibody
cdr
pdl1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017514474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534577A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/050051 external-priority patent/WO2016044189A1/en
Publication of JP2017534577A publication Critical patent/JP2017534577A/ja
Publication of JP2017534577A5 publication Critical patent/JP2017534577A5/ja
Withdrawn legal-status Critical Current

Links

JP2017514474A 2014-09-15 2015-09-14 Pd−1軸結合拮抗薬及びil−17結合拮抗薬を使用したがんの治療方法 Withdrawn JP2017534577A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462050745P 2014-09-15 2014-09-15
US62/050,745 2014-09-15
PCT/US2015/050051 WO2016044189A1 (en) 2014-09-15 2015-09-14 Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020143036A Division JP2021001176A (ja) 2014-09-15 2020-08-26 Pd−1軸結合拮抗薬及びil−17結合拮抗薬を使用したがんの治療方法

Publications (2)

Publication Number Publication Date
JP2017534577A JP2017534577A (ja) 2017-11-24
JP2017534577A5 true JP2017534577A5 (https=) 2018-10-25

Family

ID=54325043

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017514474A Withdrawn JP2017534577A (ja) 2014-09-15 2015-09-14 Pd−1軸結合拮抗薬及びil−17結合拮抗薬を使用したがんの治療方法
JP2020143036A Pending JP2021001176A (ja) 2014-09-15 2020-08-26 Pd−1軸結合拮抗薬及びil−17結合拮抗薬を使用したがんの治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020143036A Pending JP2021001176A (ja) 2014-09-15 2020-08-26 Pd−1軸結合拮抗薬及びil−17結合拮抗薬を使用したがんの治療方法

Country Status (5)

Country Link
US (3) US20170274073A1 (https=)
EP (1) EP3194440A1 (https=)
JP (2) JP2017534577A (https=)
CN (1) CN106687135A (https=)
WO (1) WO2016044189A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
WO2017136497A1 (en) * 2016-02-03 2017-08-10 The Cleveland Clinic Foundation Detection and treatment of il-17 and il-13 related conditions
AU2017248061A1 (en) * 2016-04-08 2018-10-25 Centre Antoine Lacassagne Methods and kits for predicting the sensitivity of a subject suffering of renal cancer to cancer treatment
WO2018027524A1 (en) * 2016-08-09 2018-02-15 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibody formulation
US20190270802A1 (en) * 2016-10-21 2019-09-05 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and an il-27 antagonist
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
US11220550B2 (en) * 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
US11299540B2 (en) 2017-06-18 2022-04-12 Kindred Biosciences, Inc. IL17A antibodies and antagonists for veterinary use
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules
CA3084370A1 (en) * 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
US12109249B2 (en) 2018-01-30 2024-10-08 University Of Louisville Research Foundation Compositions and methods for treating inflammation and cancer
JP2021524744A (ja) * 2018-05-21 2021-09-16 ナノストリング テクノロジーズ,インコーポレイティド 分子遺伝子シグネチャーとその使用方法
CN110563842B (zh) * 2018-06-06 2022-07-29 浙江博锐生物制药有限公司 针对程序性死亡配体(pd-l1)的抗体及其应用
KR102091637B1 (ko) * 2018-07-10 2020-03-20 연세대학교 산학협력단 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
CN109053891B (zh) * 2018-09-17 2021-12-21 苏州泓迅生物科技股份有限公司 一种抗pd-l1抗体及其制备方法和应用
WO2020150208A1 (en) * 2019-01-14 2020-07-23 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer using il-17 signaling inhibitors and immune checkpoint inhibitors
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
PT3946377T (pt) * 2019-04-03 2026-03-09 Univ Montpellier Terapias de combinação baseadas em inibidores da pd1 e il-17b
WO2020218322A1 (ja) * 2019-04-23 2020-10-29 国立大学法人東北大学 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果予測
WO2021202959A1 (en) * 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
US20230167497A1 (en) * 2020-04-30 2023-06-01 Xiaohua Xue Methods of identifying modulators of the il-17 pathway
CN119497573A (zh) * 2022-07-29 2025-02-21 金凤实验室 一种表达il-8的非人哺乳动物模型及其用途
WO2025003035A1 (en) * 2023-06-30 2025-01-02 Universitätsklinikum Essen Il-17 based therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32038A (es) * 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
US20110293629A1 (en) * 2010-05-14 2011-12-01 Bastid Jeremy Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
MX368257B (es) * 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
KR20140068877A (ko) * 2011-08-17 2014-06-09 제넨테크, 인크. 불응성 종양에서의 혈관신생의 억제
KR101463325B1 (ko) * 2013-01-14 2014-11-20 가톨릭대학교 산학협력단 HtrA2 단백질을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물

Similar Documents

Publication Publication Date Title
JP2017534577A5 (https=)
JP2017501167A5 (https=)
FI4141032T3 (fi) T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
JP2023123726A5 (https=)
JP2021514973A5 (https=)
JP2020500538A5 (https=)
JP2016510002A5 (https=)
JP2017514461A5 (https=)
JP2016505546A5 (https=)
JP2018035138A5 (https=)
JP2015509947A5 (https=)
JP2018521638A5 (https=)
RU2017114341A (ru) Антитела к pd-l1, связывающие pd-l1 собаки
JP2017507900A5 (https=)
JP2018108081A5 (https=)
JP2017113028A5 (https=)
JP2017501157A5 (https=)
JP2014158469A5 (https=)
JP2018508483A5 (https=)
JP2013198490A5 (https=)
HRP20200767T1 (hr) Humanizirana anti-humana cd19 protutijela i postupci uporabe
JP2017528476A5 (https=)
RU2008149918A (ru) Антитела к nkg2a и их применения
JP2018507220A5 (https=)
RU2011117237A (ru) АНТИТЕЛА ПРОТИВ Notch2 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ